Search research articles
Contact Us
Filters
Showing results (321-330 of 538) with videos related to
Page
of 54
Sort By:
Atherosclerosis
|
April 1, 1991
Differential role of apolipoprotein AI-containing particles in cholesterol efflux from adipose cells
A Barkia, P Puchois, N Ghalim, et al.
The American Journal of Clinical Nutrition
|
April 1, 1997
Circadian variation of postprandial lipemia
M Romon, C Le Fur, P Lebel, et al.
American Journal of Nephrology
|
January 1, 1996
Neutral-lipid transfers and cholesteryl ester transfer protein in hemodialyzed patients
V Reade, H Mezdour, R Reade, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry
|
September 15, 1977
[Exact determination of the lecithin/sphingomyelin ratio in amniotic fluid. Suggestion of a reference methods (author's transl)]
J C Fruchart, A Ponthieu, N Porchet, et al.
The American Journal of Medicine
|
November 27, 1987
Effect of fenofibrate treatment on type III hyperlipoproteinemia
J C Fruchart, J Davignon, J M Bard, et al.
Progress in Clinical and Biological Research
|
January 1, 1988
Effect of fenofibrate on apolipoprotein B containing lipoprotein particles
J C Fruchart, J M Bard, C Fievet, et al.
Lipids
|
April 3, 1999
Effects of Pinus pinaster and Pinus koraiensis seed oil supplementation on lipoprotein metabolism in the rat
G Asset, B Staels, R L Wolff, et al.
The Journal of Clinical Investigation
|
August 1, 1995
Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor
N Vu-Dac, K Schoonjans, V Kosykh, et al.
Metabolism: Clinical and Experimental
|
November 1, 1995
Comparison of the effect of fluvastatin, an hydroxymethyl glutaryl coenzyme A reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by apolipoprotein composition
J M Bard, J Dallongeville, E Hagen, et al.
Farmaco (Societa Chimica Italiana : 1989)
|
February 1, 1991
Pharmacomodulation of 7-(2-methylene-butyryl)-2,3-dihydrobenzoxazin-[1,4]-3-one structure and normolipemic activity
Z Moussavi, P Depreux, D Lesieur, et al.
Page
of 54
Search research articles
Search
Showing results (321-330 of 538) with videos related to
Sort By:
Page
of 54
Atherosclerosis
|
April 1, 1991
Differential role of apolipoprotein AI-containing particles in cholesterol efflux from adipose cells
A Barkia, P Puchois, N Ghalim, et al.
The American Journal of Clinical Nutrition
|
April 1, 1997
Circadian variation of postprandial lipemia
M Romon, C Le Fur, P Lebel, et al.
American Journal of Nephrology
|
January 1, 1996
Neutral-lipid transfers and cholesteryl ester transfer protein in hemodialyzed patients
V Reade, H Mezdour, R Reade, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry
|
September 15, 1977
[Exact determination of the lecithin/sphingomyelin ratio in amniotic fluid. Suggestion of a reference methods (author's transl)]
J C Fruchart, A Ponthieu, N Porchet, et al.
The American Journal of Medicine
|
November 27, 1987
Effect of fenofibrate treatment on type III hyperlipoproteinemia
J C Fruchart, J Davignon, J M Bard, et al.
Progress in Clinical and Biological Research
|
January 1, 1988
Effect of fenofibrate on apolipoprotein B containing lipoprotein particles
J C Fruchart, J M Bard, C Fievet, et al.
Lipids
|
April 3, 1999
Effects of Pinus pinaster and Pinus koraiensis seed oil supplementation on lipoprotein metabolism in the rat
G Asset, B Staels, R L Wolff, et al.
The Journal of Clinical Investigation
|
August 1, 1995
Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor
N Vu-Dac, K Schoonjans, V Kosykh, et al.
Metabolism: Clinical and Experimental
|
November 1, 1995
Comparison of the effect of fluvastatin, an hydroxymethyl glutaryl coenzyme A reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by apolipoprotein composition
J M Bard, J Dallongeville, E Hagen, et al.
Farmaco (Societa Chimica Italiana : 1989)
|
February 1, 1991
Pharmacomodulation of 7-(2-methylene-butyryl)-2,3-dihydrobenzoxazin-[1,4]-3-one structure and normolipemic activity
Z Moussavi, P Depreux, D Lesieur, et al.
Page
of 54